Welcome to our dedicated page for Veracyte news (Ticker: VCYT), a resource for investors and traders seeking the latest updates and insights on Veracyte stock.
Veracyte, Inc. reports developments in cancer diagnostics, with recurring updates centered on its Veracyte Diagnostics Platform and genomic tests used in prostate, thyroid, bladder, and breast cancer. Company news frequently covers Decipher Prostate, Decipher Bladder, Afirma, Prosigna, and development work in whole-genome minimal residual disease and multi-omics applications.
Veracyte updates commonly include quarterly financial results, testing revenue and volume trends, clinical evidence presented at oncology and urology meetings, real-world data analyses, product-development capabilities, and leadership roles tied to assay development, software, bioinformatics, and AI-enabled diagnostics.
Veracyte, Inc. (NASDAQ: VCYT) has published new data on its Afirma Genomic Sequencing Classifier (GSC) demonstrating its effectiveness in reducing unnecessary surgeries for patients with indeterminate thyroid nodules. The peer-reviewed study showed that Afirma GSC identified 30% more benign nodules compared to the original classifier, leading to a 41% reduction in surgeries compared to patients without molecular testing. The research reinforces the test's high sensitivity and specificity, indicating a shift in clinical practice for managing thyroid nodules.
Veracyte, Inc. (NASDAQ: VCYT) announced the presentation of three abstracts at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting from November 10-14, 2021. These abstracts focus on the company's Brightplex technology, acquired from HalioDx, which analyzes tumor micro-environments to enhance immunotherapy development. Corinne Danan, general manager of Biopharma, emphasized the importance of this technology in understanding therapeutic mechanisms. Veracyte aims to improve cancer treatment through innovative diagnostic solutions that speed up patient care.
Veracyte (NASDAQ: VCYT) presented new data at the ASTRO Annual Meeting 2021, indicating that its Decipher Prostate genomic classifier is effective in tailoring treatment for men with prostate cancer after radical prostatectomy. Results from a phase 3 trial involving 226 patients showed that those classified as high-risk using the Decipher tool had over double the likelihood of experiencing cancer progression with radiotherapy alone. This study highlights the potential for personalized treatment plans, enhancing outcomes for patients with rising PSA levels.
Veracyte (Nasdaq: VCYT) announced at the ASTRO 2021 Annual Meeting that its Decipher Prostate genomic classifier has validated the identification of patients with high-risk prostate cancer requiring intensified treatment. An analysis of biopsy samples indicated that high Decipher scores correlated with worse outcomes, including distant metastases and mortality. The data, derived from three phase 3 randomized trials, show that men with high-risk scores faced a cumulative incidence of metastases of 41% at 10 years. This validation may enhance personalized treatment decisions in clinical settings.
Veracyte (NASDAQ: VCYT) will present new data on its Decipher Prostate genomic test at the ASTRO Annual Meeting 2021, taking place from October 24-27 in Chicago. The studies focus on the test's effectiveness for newly diagnosed, clinically high-risk prostate cancer patients and those with biochemical disease progression after prostatectomy. Notable presentations include two oral sessions scheduled for October 25 and 26, showcasing its potential role in personalized treatment decision-making. This advancement in genomic science aims to enhance patient care and treatment outcomes.
Veracyte, Inc. (Nasdaq: VCYT) has published new data showing that its Decipher Bladder genomic classifier effectively identifies bladder tumors likely to respond to chemotherapy before radical cystectomy. The findings, detailed in a peer-reviewed study, may enhance treatment planning for muscle-invasive bladder cancer (MIBC) patients. In a study of 601 patients, non-luminal tumors significantly benefitted from neoadjuvant chemotherapy, improving overall survival by 10%. Veracyte aims to validate this test for routine clinical use.
Veracyte, Inc (NASDAQ: VCYT) will release its Q2 2021 financial results on November 9, after market close. Management will host a conference call at 4:30 p.m. ET to discuss the results and provide a business update. Investors can join via a toll-free number or through a live webcast. Veracyte specializes in diagnostics, leveraging genomic science to enhance cancer diagnosis and treatment decisions, helping patients avoid unnecessary procedures. The company continues to develop tests across various cancers.
Veracyte (NASDAQ: VCYT) announced new findings showing that its Envisia Genomic Classifier significantly enhances clinical decision-making in idiopathic pulmonary fibrosis (IPF). An oral presentation at the CHEST Annual Meeting on October 18 will highlight the results from a study involving over 100 pulmonologists. Key metrics include a 39% increase in IPF diagnosis and a boost in physician confidence, leading to a higher rate of treatment recommendations. This innovative test addresses the critical need for accurate diagnoses in a challenging medical area.
Veracyte (Nasdaq: VCYT) has announced expanded clinical validation data supporting the Percepta Nasal Swab test, which helps assess lung cancer risk in patients with lung nodules. This noninvasive test shows high sensitivity (97%) and negative predictive value (98%) for low-risk classifications, potentially reducing unnecessary invasive procedures. The test's performance is consistent across different nodule sizes and stages of non-small cell lung cancer (NSCLC). Veracyte is offering the test to selected clinical sites, aiming to build clinical utility data for reimbursement.
Veracyte announces the presentation of four abstracts at the CHEST 2021 Annual Meeting, highlighting the clinical impact of its genomic diagnostic tests for lung cancer. The studies show that the Percepta Nasal Swab test can effectively assess cancer risk in patients with lung nodules, enhancing decision-making for treatment options. Additional findings reinforce the value of the Percepta GSC and Envisia GC in managing lung cancer and interstitial lung disease.